Biopharma News : Biopharma and Pharma news from all around the world :
- Ellipses Pharma explores a London Stock Exchange listing opportunity
- Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026
- CAI Enters Into a Definitive Agreement with PQE Group, Expanding Global Life Sciences Reach
- Avenzo Therapeutics Presents Positive Preliminary Results from the Phase 1 Study of AVZO-1418, a Potentially Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, at the 38th EORTC-NCI-AACR Symposium
- Shionogi Completes Acquisition of IntraBio Inc. and Adds AQNEURSA® (levacetylleucine) to Growing Rare Disease Global Portfolio
- Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer
- Octant Appoints Eddy Anglade, M.D., as Chief Medical Officer
- Diranersen demonstrates increasing clinical benefit at two years in early Alzheimer’s disease
- Sofinnova Partners Closes €725M Crossover II Fund
- Genentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy
- Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
- GoGoMeds Appoints Harish Panchal as Chief Executive Officer
- Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
- VedaBio Demonstrates Under-10-Minute Molecular Detection with Target Amplification-Free CRISPR Technology at AMP 2026
- Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- Thermo Fisher Scientific to Participate in UBS 2026 CEO Call Series on November 19, 2026
- Zai Lab Announces Participation in Investor Conferences in November 2026
- Zai Lab Presents Positive First-in-Human Data for ZL-1503, a Novel IL-13/IL-31Rα Bispecific, Demonstrating Rapid and Sustained Inhibition of Key Atopic Dermatitis Biomarkers and Extended Serum Half-Life Supporting Less Frequent Dosing
- Ontada Advances the Intelligent Medical Record with Integrated AI Capabilities for iKnowMed
- Inaugural Future of Oncology Summit Brings Together Leaders to Accelerate Cancer Innovation
- Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season
- SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results
- Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy
- Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane® Shaype™ for Both Chin and Its First Jawline Indication
- LEO Pharma announces NMPA-approval of Anzupgo® (delgocitinib) cream for patients with moderate to severe chronic hand eczema (CHE) in China
- Tech-Inno Health Launches Branded Ingredients Business, Highlighting Urolithin A, S-Equol and Mulberry Leaf Extract
- Vir Biotechnology Announces Pricing of Public Offering of Common Stock
- Resero Analytics Launches TurboLIMS to Accelerate Nonclinical Studies
- I2Pure Scientists Identify a Reliability Gap in Iodine Antiseptics
News about Biotech, Pharma, Biopharma, Medical Devices, Diagnostics, Digital Health
- Medios AG: Medios AG adopts public share buyback program
- Medios Approves New Share Buyback Program
- Drägerwerk AG & Co. KGaA: Dräger presents Ambition 2030: EUR 4.5 billion in net sales and a 10 to 12 percent EBIT margin
- M1 Kliniken AG’s nine-month Beauty EBIT rises 35.5% to EUR 28.6 million
- Verfora acquires majority stake in distribution partner Qpharma
- M1 Kliniken AG plans move to the Prime Standard in 2027 and raises EBIT margin target for its Beauty segment to at least 25%
- SKAN takes note of the Federal Criminal Court’s first-instance judgments
- Two Blockbusters, Two Niche-Busters, One Smart Portfolio: Formycon Names Tezspire® and Hemlibra® as Reference Drugs
- MindMaze Therapeutics Announces CHF 4 Million Financing
- Galimedix Therapeutics outlines development plans in Alzheimer’s disease at CTAD 2026
- Viromed Medical AG: Changes to the Management Board
- Viromed Medical AG Restructures Management Board for Its Next Growth Phase
- Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology
- EvoNext Holdings SA makes available the audited financial statements of Ascend Sport Technology AG for 2025/26
- Sandoz launches Enzeevu in the US and announces key private label agreement, expanding treatment choice for patients with retinal diseases
- Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- DIAGENS Leads in Two Major Global AI Benchmarks and Extends Chest and Abdominal CT Analysis to 509 Imaging Targets, Ushering in a New Era for Medical Imaging AI
- Novogenia to Contribute DNA Analytics and Personalized Dietary Supplements to Planned Clinical Study as Part of the 10XREVIV Initiative
- Pentixapharm Holding AG extends drawdown period and term of its convertible bond with Eckert & Ziegler SE to 2030 with adjusted terms
- Strong existing business in the “Branded pharmaceuticals” segment drives positive performance
- Fresenius completes sale of 13.4 million Fresenius Medical Care shares at €39.00 per share, raising approximately €524 million
- Eckert & Ziegler: Adjusted EBIT +25% in the Third Quarter. 2026 Forecast Confirmed
- Pentixapharm Reports Third Quarter and Nine Months 2026 Results, Confirms Revised 2026 Outlook
- STRATEC REPORTS FINAL RESULTS FOR FIRST NINE MONTHS OF 2026
- Lonza Appoints Bertha Steinmetz Vilela as Chief Human Resources Officer
- EvoNext Holdings SA: EGM invitation and final steps towards combination with Ascend Sport Technology AG
- Sandoz launches Ranluspec® (ranibizumab) in Europe, providing an affordable treatment option for patients with retinal diseases
- Continued strong Rx growth: DocMorris raises full-year revenue forecast as part of today’s Capital Markets Day
- Fresenius announces intention to sell approximately 13.4 million shares in Fresenius Medical Care AG, reducing its financial investment to approximately 20 per cent
- aap Implantate AG: Management Board refines 2026 forecast and provides first outlook for 2027 – Ambition 2030: Revenue of at least EUR 21 million with an EBITDA margin of 17.5% to 22.5%
- INB.bio Launches 2026 Growth Strategy With New Market Entries Across Africa, MENA and Southeast Asia
- HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
- Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026
- Akemi Hair Glow Claims Evaluated: 2026 Hair Growth Transparency Report Examines DHT-Blocking Spray Research, “56% Thicker Hair” Data, and Ingredient Research for Women
- IBA Launches myQAMatriXXAiR to Advance Patient‑Specific QA in Particle Therapy
- Financière de Tubize – Annual report 2025
- Garaherb Claims Evaluated: Complete Scientific Investigation of Ingredients’ Effectiveness
- Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
- Disclosure of a transparency notification from Aberdeen Group plc
- SafeSpace Global Corporation Reports Q2 Fiscal 2026 Financial Results; Company Transitions from Pre-Revenue to Revenue-Generating Stage, Expands Footprint with Nashville Office, and Initiates Steps Toward National Exchange Uplisting
- Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
- Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
- Longeviti Neuro Solutions Appoints T. Rowe Price CEO Robert W. Sharps to Board of Directors
- BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT
- RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
- WallabyPhenox Announces First U.S. Patient Treated with p48 & p64 MW HPC Flow Modulation Devices in PIANO IDE Trial
- Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis
- Picard Medical / SynCardia to Present its Next-Generation Emperor Total Artificial Heart Technology at the American College of Cardiology’s Annual Scientific Session
- Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
- Human Appeal to deliver food aid to thousands of displaced civilians as part of initial response in Lebanon
- BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
- BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
- Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update
- Pacific Health Care Organization, Inc. Reports its 2025 Year-End Financial Results
- Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
- BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025
- New partnership to fast-track Canadian health technology from innovation to patient care
- Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions
- Cosmos Health Provides Update; Evaluates Options to Address Valuation Disconnect; Will Issue Updated Guidance Following FY 2025 Results; Record Growth Continues as Significant U.S. Expansion Underway, with Additional $12M+ in High-Margin Revenue Projected; Important R&D Updates Expected Following Finalization of Certain Anticipated Transactions
- New partnership to fast-track Canadian health technology from innovation to patient care
Sources for this page of Biopharma News : biopharma-reporter.com and worldpharmanews and pharmatimes.com and drugs.com and fiercepharma.com and scripintelligence.com and PR Newswire and Business Wire. Please visit all this very interesting websites for more info.
Biopharma News – Pharma News
